Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06154278 · ClinicalTrials.gov registry record · Phase 2
Intrahepatic and Peripheral Responses to Imdusiran (AB-729) in Chronic Hepatitis B
A Phase 2 study of Chronic Hepatitis B, sponsored by University of Maryland, Baltimore.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT06154278 is a Phase 2 study of Chronic Hepatitis B that is actively recruiting participants, run by University of Maryland, Baltimore. The registered enrollment target is 10 participants, below the 293-participant average among 14 other Chronic Hepatitis B trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06154278, a Phase 2 study of Chronic Hepatitis B, is actively recruiting participants, sponsored by University of Maryland, Baltimore.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn about the action of Imdusiran (AB-729) in the liver of people with chronic hepatitis B. The main questions it aims to answer are: * how well is it working in the liver * how does Imdusiran affect the hepatitis B virus Participants will receive injections of Imdusiran, one injection every 8 weeks, for a total of 4 doses. They will also undergo 2 liver biopsies: one with the first dose of Imdusiran, and the second 8 weeks after the last dose of Imdusiran.
Conditions Studied
Interventions
- DRUG Imdusiran (AB-729)
Study Locations (1)
Maryland
- Institute of Human Virology, University of Maryland School of Medicine - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2024-07-25 |
| Est. Completion | 2027-07-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06154278
The ClinicalTrials.gov registry entry for NCT06154278 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 293-participant average among 14 other Chronic Hepatitis B trials with a reported enrollment target (97% lower). The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Hepatitis B appearing as the primary indexed condition, and to 1 intervention - of which Imdusiran (AB-729) is the first listed.
NCT06154278 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT06154278 about?
NCT06154278 is a clinical study titled "Intrahepatic and Peripheral Responses to Imdusiran (AB-729) in Chronic Hepatitis B". The goal of this clinical trial is to learn about the action of Imdusiran (AB-729) in the liver of people with chronic hepatitis B. The main questions it aims to answer are: * how well is it working in the liver * how does Imdusiran affect the hepatitis B virus Participants will receive injections...
What is the current status of trial NCT06154278?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2024-07-25. Estimated completion is 2027-07-01.
What conditions does trial NCT06154278 study?
This clinical trial studies the following conditions: Chronic Hepatitis B.
What interventions are being tested in trial NCT06154278?
The interventions under investigation include: Imdusiran (AB-729) (DRUG).
Who is sponsoring clinical trial NCT06154278?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06154278 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Hepatitis B
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B
RECRUITING · Phase 2
-
Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection
RECRUITING · Phase 2
-
Add-on Peginterferon Following Nucleos(t)Ide Analogue Treatment
COMPLETED · Phase 2
-
Safety and Efficacy of GS-4774 in Combination With Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Participants With Chronic Hepatitis B (CHB) and Who Are Currently Not on Treatment
COMPLETED · Phase 2
-
Study To Evaluate Safety and Efficacy of Vesatolimod for the Treatment of Chronic Hepatitis B Virus in Virally-Suppressed Participants
COMPLETED · Phase 2
-
Study to Evaluate the Safety, Tolerability, and Efficacy of Vesatolimod in Combination With Tenofovir Disoproxil Fumarate (TDF) in Adults With Chronic Hepatitis B (CHB) Infection Who Are Currently Not Being Treated
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.